Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline
复制标题
DOI：
10.1086/526775
复制
发表时间：
2008-02-15
影响因子：
11.8
通讯作者：
Lautenbach, Ebbing
中科院分区：
文献类型：
--
作者：
Anthony, Kara B.;Fishman, Neil O.;Lautenbach, Ebbing
18名患者接受替格环素治疗多重耐药革兰氏阴性杆菌感染，包括鲍曼不动杆菌和肺炎克雷伯菌碳青霉烯酶和超广谱β-内酰胺酶产生菌。替加环素治疗前的最低抑菌浓度值预测临床成功。在治疗过程中观察到的耐药性演变引起了人们的担忧，即当有其他治疗方法可用时，在此类感染的治疗中常规使用替吉环素。
Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase - and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.